Laura Llorca Otero1, Rosa Girón Moreno2, Buenaventura Buendía Moreno3, Claudia Valenzuela2, Alba Guiu Martínez3, Teresa Alarcón Cavero3. 1. Department of Microbiology, Instituto de Investigación Sanitaria, Hospital Universitario de la Princesa, Diego de León, 62, Madrid, Spain. Electronic address: laurallorcaotero@gmail.com. 2. Department of Pulmonology, Instituto de Investigación Sanitaria, Hospital Universitario de la Princesa, Diego de León, 62, Madrid, Spain. 3. Department of Microbiology, Instituto de Investigación Sanitaria, Hospital Universitario de la Princesa, Diego de León, 62, Madrid, Spain.
Abstract
BACKGROUND: Achromobacter xylosoxidans is an emerging pathogen in cystic fibrosis (CF). Although the rate of colonization by this microorganism is variable, prevalence is increasing in CF units. METHODS: A microbiological/clinical study was conducted on of adult CF patients harboring A. xylosoxidans. Identification and susceptibility testing were performed using MicroScan (Siemens). Decline in lung function was assessed using the variable, annual percentage loss of FEV1 (forced expiratory volume in 1s). RESULTS: A. xylosoxidans was isolated in 18 (19.8%) of 91 patients over a 14-year period. Mean age was 26.6 years (18-39 years). Nine patients (9.8%) were chronically colonized. Piperacillin/tazobactam and imipenem were the most active antibiotics. Mean annual decline in lung function in chronically colonized patients was 2.49%. CONCLUSIONS: A. xylosoxidans is a major pathogen in CF. A decreased lung function was observed among patients who were chronically colonized by A. xylosoxidans. Antibiotic therapy should be started early in order to prevent chronic colonization by this microorganism.
BACKGROUND:Achromobacter xylosoxidans is an emerging pathogen in cystic fibrosis (CF). Although the rate of colonization by this microorganism is variable, prevalence is increasing in CF units. METHODS: A microbiological/clinical study was conducted on of adult CF patients harboring A. xylosoxidans. Identification and susceptibility testing were performed using MicroScan (Siemens). Decline in lung function was assessed using the variable, annual percentage loss of FEV1 (forced expiratory volume in 1s). RESULTS:A. xylosoxidans was isolated in 18 (19.8%) of 91 patients over a 14-year period. Mean age was 26.6 years (18-39 years). Nine patients (9.8%) were chronically colonized. Piperacillin/tazobactam and imipenem were the most active antibiotics. Mean annual decline in lung function in chronically colonized patients was 2.49%. CONCLUSIONS:A. xylosoxidans is a major pathogen in CF. A decreased lung function was observed among patients who were chronically colonized by A. xylosoxidans. Antibiotic therapy should be started early in order to prevent chronic colonization by this microorganism.
Authors: B D Edwards; J Greysson-Wong; R Somayaji; B Waddell; F J Whelan; D G Storey; H R Rabin; M G Surette; M D Parkins Journal: J Clin Microbiol Date: 2017-04-26 Impact factor: 5.948
Authors: Erin P Price; Valentina Soler Arango; Timothy J Kidd; Tamieka A Fraser; Thuy-Khanh Nguyen; Scott C Bell; Derek S Sarovich Journal: Microb Genom Date: 2020-07-15